Home » Stocks » IMV Inc.

IMV Inc. (IMV)

Stock Price: $3.19 USD -0.20 (-5.77%)
Updated Oct 26, 2020 1:16 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 213.69M
Revenue (ttm) 433,588
Net Income (ttm) -27.37M
Shares Out 67.09M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $3.19
Previous Close $3.38
Change ($) -0.20
Change (%) -5.77%
Day's Open 3.34
Day's Range 3.19 - 3.39
Day's Volume 143,678
52-Week Range 1.35 - 6.82

More Stats

Market Cap 213.69M
Enterprise Value 210.41M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 67.09M
Float 59.00M
EPS (basic) n/a
EPS (diluted) -0.34
FCF / Share -0.43
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.05M
Short Ratio 3.30
Short % of Float 1.77%
Beta 2.06
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 492.85
PB Ratio 13.44
Revenue 433,588
Operating Income -19.94M
Net Income -27.37M
Free Cash Flow -21.19M
Net Cash 3.28M
Net Cash / Share 0.05
Gross Margin 100.00%
Operating Margin -4,599.65%
Profit Margin -4,817.80%
FCF Margin -4,888.03%
ROA -51.40%
ROE -153.40%
ROIC -242.90%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 4
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.77*
(143.96% upside)
Low
3.00
Current: $3.19
High
11.00
Target: 7.77
*Average 12-month USD price target from 6 stock analysts.

Financial Performance

Financial numbers in millions CAD.

Financial Overview

Year2019201820172016
Revenue0.570.480.220.13
Revenue Growth17.6%117.57%71.16%-
Gross Profit0.570.480.220.13
Operating Income-26.13-20.55-11.06-8.37
Net Income-27.37-21.94-12.03-8.77
Shares Outstanding49.6543.7738.6691.87
Earnings Per Share-0.55-0.50-0.31-0.10
Operating Cash Flow-27.29-17.22-9.00-7.07
Capital Expenditures-0.48-2.17-0.39-0.12
Free Cash Flow-27.76-19.39-9.38-7.19
Cash & Equivalents14.0714.9014.913.84
Total Debt9.779.556.543.78
Net Cash / Debt4.305.358.370.07
Assets22.4322.9317.035.95
Liabilities15.9918.6110.695.88
Book Value6.454.326.340.07
Numbers in millions CAD, except per-share numbers.

Company Profile

Company Details

Full Name IMV Inc.
Country Canada
Employees 62
CEO Frederic Ors

Stock Information

Ticker Symbol IMV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMV

Description

IMV, a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.